A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Binimetinib (Primary) ; Ribociclib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma; Novartis Pharmaceuticals; Pfizer
- 16 Mar 2022 Results published in the Clinical Cancer Research
- 12 Jul 2019 Trial has been completed in Germany, according to European Clinical Trials Database record.
- 22 Feb 2018 Status changed from active, no longer recruiting to completed.